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Prognostic Significance of Controlled
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Cristina Margini, Giuseppe Murgia, Guido Stirnimann, Andrea De Gottardi, Nasser Semmo, Stefania Casu, Jaime Bosch,
Jean-Franc¸ois Dufour, and Annalisa Berzigotti
Obesity and steatosis have been associated with liver disease progression in patients with compensated advanced chronic liver
disease (cACLD) (liver stiffness measurement [LSM]  10 kPa). The controlled attenuation parameter (CAP) estimates steato-
sis during LSM by transient elastography. We aimed to evaluate whether CAP is associated with the development of clinically
relevant events in cACLD. Consecutive patients with cACLD and CAP measurements observed between September 2013 and
September 2015 were retrospectively studied. Classical decompensation and severe bacterial infections on follow-up were
recorded. A predeﬁned CAP cut-off for steatosis was used (220 dB/m; 90% sensitivity). The association among LSM, CAP,
and events was assessed by univariate and multivariate Cox regression. Among the 193 patients (viral etiology 5 58%; median
Child score5 5; LSM5 15.1 kPa; CAP5 2556 62 dB/m) who were followed up in median for 18 months, 18 developed clin-
ically relevant events (11 liver decompensation, 7 severe bacterial infections). Patients developing events had higher LSM
(median: 30.8 versus 14.3 kPa, P < 0.001) and showed trends for higher CAP (275 6 46 versus 252 6 63 dB/m, P 5 0.07),
lower platelet count (134 6 74 versus 167 6 74 G/L, P 5 0.07), and worse liver function versus patients remaining compen-
sated. Body mass index was similar in the two groups. All events were more frequent in patients with CAP being greater than or
equal to 220 dB/m (12.9% versus 1.6% in CAP < 220; P 5 0.013), and 10 of 11 episodes of liver decompensation occurred in
patients with CAP being greater than or equal to 220 dB/m. Following multivariate analysis, LSM and CAP greater than or
equal to 220 dB/m remained independently associated with clinical events in the whole population and in patients with clinically
signiﬁcant portal hypertension. Conclusion: The CAP being greater than or equal to 220 dB/m is associated with increased risk
of clinical decompensation and bacterial infections independent of LSM in patients with cACLD and allows reﬁning the nonin-
vasive risk stratiﬁcation in this population. (Hepatology Communications 2018;2:929-940)
The natural history of advanced chronic liverdisease (ACLD) is characterized by a long,asymptomatic compensated phase in which
the median survival is around 12 years.(1) Once clinical
decompensation occurs, the expected median survival
dramatically drops to a median of 2 years.(1) There-
fore, the goal of therapy in patients with com-
pensated ACLD (cACLD) is to prevent clinical
Abbreviations: ACLD, advanced chronic liver disease; BMI, body mass index; cACLD, compensated advanced chronic liver disease; CAP, controlled
attenuation parameter; CSPH, clinically signiﬁcant portal hypertension; DAA, direct antiviral agent; GGT, gamma-glutamyltransferase; HBV, hepati-
tis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; LSM, liver stiffness measurement; MELD,
Model for End-Stage Liver Disease; NIT, noninvasive tool.
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decompensation.(2,3) More recently, it has been shown
that bacterial infections should be considered as clini-
cally relevant events in patients with liver disease, as
they worsen prognosis independent of the clinical
stage.(4)
Because the risk of developing clinical decompensa-
tion in cACLD is largely variable, risk stratiﬁcation is
a major need to individualize care.(2) Clinically signiﬁ-
cant portal hypertension (CSPH), measured by its
invasive surrogate hepatic venous pressure gradient (
10 mmHg),(5) and liver function, estimated by serum
albumin and the Model for End-Stage Liver Disease
(MELD) score, are among the most consistent varia-
bles associated with prognosis in cACLD(1) and inde-
pendently predicted the ﬁrst clinical decompensation
in patients with histologically proven compensated cir-
rhosis included in a long-term randomized controlled
trial of timolol versus placebo for preprimary prophy-
laxis of gastroesophageal varices.(6)
The availability of noninvasive tools (NITs), partic-
ularly the liver stiffness measurement (LSM) by using
transient elastography, greatly simpliﬁes the identiﬁca-
tion of cACLD, leading to a much higher proportion
of patients being diagnosed in this early stage of the
disease.(3)
According to the recommendations of the Baveno
VI consensus conference, LSM greater than or equal
to 10 kPa should be used to suspect cACLD (cut-off
with >90% sensitivity) and LSM greater than or equal
to 15 kPa is diagnostic of cACLD (cut-off with >90%
speciﬁcity).(2) In addition, because a LSM greater than
or equal to 21 kPa yields a speciﬁcity of greater than
90% for CSPH,(7) and this cut-off is as accurate as the
invasive ﬁnding of CSPH to predict ﬁrst clinical
decompensation,(8) the Baveno VI recommendations
supporting the use of LSM in the initial risk stratiﬁca-
tion of patients diagnosed with cACLD.(2,7)
Obesity has been proposed as an additional unfavor-
able prognostic factor in compensated patients with
ACLD, but data in this regard are still limited. In the
timolol study cohort, body mass index (BMI) was
strongly associated with the risk of clinical decompen-
sation independent of portal hypertension and albu-
min(9); and in cACLD due to chronic hepatitis C
(HALT-C study), the BMI predicted the progression
of ﬁbrosis on histology and the onset of clinical
events.(10) In the latter study, when the presence of
liver steatosis on histology was analyzed together with
BMI on a multivariate analysis, only liver steatosis
remained independently associated with the clinical
endpoints,(10) suggesting that accurate information on
the presence or absence of liver steatosis could improve
the prognostic stratiﬁcation of cACLD.
The controlled attenuation parameter (CAP) is a
recently developed quantitative, objective NIT for liver
steatosis assessment, which measures the attenuation
of ultrasound waves transmitted at a known frequency
in the liver parenchyma.(11) The CAP values are
obtained simultaneously to LSM using the same
device,(11-13) and the estimation of liver fat through
this method is reliable.(14-18) The CAP values of 215
to 238 dB/m hold a high sensitivity for the detection
of steatosis in patients with chronic liver disease of
different etiologies,(14-18) and in one study CAP and
proton magnetic resonance spectroscopy showed com-
parable accuracy for the detection of hepatic steatosis
in patients.(14)
In the present study we hypothesized that CAP,
using a cut-off with high sensitivity for the detection
of steatosis, might be used as a noninvasive predictor
of prognosis in patients with cACLD, and could
improve the risk stratiﬁcation for clinically relevant
events and clinical decompensation provided by LSM
in this population.
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Materials and Methods
STUDYDESIGNANDPOPULATION
This is an observational, retrospective, single-center
cohort study. The Cantonal Ethical Committee of Bern
approved the present study (EK BE 2017-00501).
All consecutive patients with chronic liver disease
who underwent an LSM by transient elastography
between September 2013 and September 2015 in our
outpatient clinic (Hepatology Department, University
Clinic for Visceral Surgery and Medicine, Inselspital,
Bern, Switzerland) were screened as potential candi-
dates for inclusion in the study.
Patients were enrolled if they fulﬁlled the following
inclusion criteria: clinically compensated (no presence or
history of ascites, bleeding, jaundice, hepatic encepha-
lopathy, or sepsis); LSM greater than or equal to 10
kPa, which is compatible with advanced chronic liver
disease(2); available concomitant CAP measurement
(age  18 years); available clinical data at baseline; and
at least 6 months of follow-up. Exclusion criteria
included all of the following: unreliable LSM deﬁned
by interquartile range/median greater than or equal to
0.30(19) and previous or ongoing decompensation of
liver disease deﬁned as ascites, bleeding from portal
hypertensive sources, jaundice, hepatic encephalopathy,
severe bacterial infections leading to hospitalization, and
hepato-renal syndrome. Patients with previous liver
transplantation, vascular liver disease, hepatocellular car-
cinoma (HCC) beyond the Milano criteria (alanine
aminotransferase > 300 U/L),(19) or denial of the use of
personal health–related data were also excluded.
A ﬂowchart illustrating the selection process is pro-
vided in Fig. 1.
LIVER STIFFNESSMEASUREMENT
ANDCONTROLLEDATTENUATION
PARAMETERASSESSMENT
Transient elastography (Fibroscan 502 Touch;
Echosens, Paris, France) provided with M probe was
used to assess LSM and CAP. The CAP was available
only on M probe during the inclusion period. Meas-
urements were performed in fasting conditions during
a routine visit at our outpatient facility.
The following previously published cut-offs of LSM
were predeﬁned for the analysis: LSM  15 kPa: deﬁ-
nite cACLD(2); LSM < 13.6 kPa: unlikely clinically
signiﬁcant portal hypertension (sensitivity 90%); LSM
 21 kPa: high likelihood of clinically signiﬁcant por-
tal hypertension (speciﬁcity 90%).(7)
As for CAP, because the presence of any steatosis
was associated with a worse prognosis in a previous
report using histological data,(10) to avoid false-negative
results we selected two previously published cut-offs
with sensitivity close to 90%, namely, 220 and 235 dB/
m, which we used to discriminate patients without stea-
tosis versus those with likely liver steatosis.(14-18)
Demographic, Clinical,
and Laboratory Data
We collected the demographic, clinical, and labora-
tory data paired to LSM and CAP measurement.
Clinical data included etiology of liver disease, BMI,
                                                                 
FIG. 1. Flowchart of the inclusion and exclusion process; 193
patients were included.
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presence of diabetes, arterial hypertension and dyslipi-
demia, and ongoing medication for each of these con-
ditions. For patients who underwent screening/
surveillance endoscopy, data on the presence of gastro-
esophageal varices and ongoing primary prophylaxis
with nonselective beta-blockers were collected. Labo-
ratory data included aspartate aminotransferase/alanine
aminotransferase, gamma-glutamyltransferase (GGT),
alkaline phosphatase, creatinine, bilirubin, albumin,
glucose, sodium, potassium, platelet count, and inter-
national normalized ratio (INR). Bipolar diameter of
the spleen on imaging obtained within 3 months of
inclusion (ultrasound or computed tomography scan)
was also collected.
According to the World Health Organization rec-
ommendations, BMI was categorized as < 18 kg/m2:
underweight; 18-24.99 kg/m2: normal weight; 25-29.9
kg/m2: overweight;  30 kg/m2: obese.
In patients on oral anticoagulants, INR was not
used and MELD was not calculated.
Clinical Decompensation of Liver
Disease and Severe Bacterial Infections
in the Follow-up
Patients were followed up every 6 months until Febru-
ary 2017 or until death or liver transplantation. The sta-
tus of patients lost to follow-up was censored to the date
of the last follow-up available. A minimal follow-up of 6
months was required and patients not meeting this crite-
rion were excluded. Clinical decompensation was deﬁned
as the occurrence of one of the following: ascites, bleeding
from gastroesophageal varices, jaundice, hepatic encepha-
lopathy, or hepato-renal syndrome. Severe bacterial infec-
tions requiring hospitalization were considered as relevant
clinical events and were recorded.(8) Liver transplantation
and death were also recorded, and the date of each event
was entered in the database.
Statistical Analysis
The Kolmogorov–Smirnov test was used to test
whether variables were normally distributed. A P value
greater than 0.05 was required to assume a normal
distribution. Continuous variables are expressed as
mean6 standard deviation or median (interquartile
range), and categorical variables are expressed as num-
bers or percentages. Chi-square, Student t, and Mann-
Whitney U tests were used according to variable char-
acteristics. Pearson’s test was used for correlations.
Comparisons among the three groups were performed
using the Kruskal-Wallis test and one-way analysis of
variance. Patients undergoing liver transplantation
were censored at the time of transplant. Variables with
over 30% missing values were not used for the analysis.
Risk factors for all clinical events and for clinical
decompensation were assessed by univariate Cox logis-
tic regression analysis. Variables with P less than 0.10
in patients developing events versus remaining com-
pensated were included in a Cox’s multivariate step-
wise regression analysis to analyze the independent
effect of each variable on the outcome; by default, vari-
ables were included in the ﬁnal step of the model if P
was greater than 0.10. One variable for every ﬁve
events was included in the multivariate model.(20)
Kaplan-Meier’s curves were constructed and compared
with the log-rank test. Data were analyzed using
PAWS statistics version 23 (SPSS Inc., Chicago, IL).
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
BASELINE CHARACTERISTICS
Among the 334 patients initially considered, 193
fully compensated patients were included in the study
(Fig. 1) and were followed up for a median of 18
months (range 6-40). The main clinical and biochemi-
cal characteristics on inclusion are presented in Table
1. Three patients were receiving oral anticoagulants for
non-liver-related conditions.
As shown, the median Child and MELD scores
were low, as expected in a population of well-
compensated patients.
Regarding the 98 patients with liver disease due to
chronic hepatitis C virus (HCV) (alone in 90 cases,
HCV1 hepatitis B virus [HBV] in 2, HCV1 alcohol
in 6), 12 were HCV-RNA negative on inclusion
(spontaneous clearance of the virus in 2; sustained viro-
logical response after antiviral drugs in 10). A total of
86 patients were HCV-RNA positive on inclusion;
among them, 72 (84%) were successfully treated with
direct antiviral agents (DAAs) during the follow-up.
Seventeen patients had liver disease due to HBV
(HBV alone in 15, HCV 1 HBV in 2); among these
patients, 10 were under anti-HBV antiviral therapy on
inclusion.
Twenty-one patients had liver disease due to exces-
sive alcohol consumption. Among them, 8 patients
were abstinent on inclusion and one of them had
recurrence of alcohol consumption during follow-up.
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Of the 13 patients not abstinent on inclusion, 9
became abstinent during follow-up.
The status of varices was known on inclusion in 94 of
193 patients (48.7%), 41 of 94 (44%) patients in whom
an endoscopy was available had gastroesophageal vari-
ces. Fourteen (7%) patients were on nonselective beta-
blockers on inclusion.
Body mass index at baseline was available in 183 of
193 (94.8%) patients. Among them, 44.8% were over-
weight and 21.3% were obese (Table 1; 13 patients
had a BMI > 35 kg/m2). Two patients (1.1%) were
underweight.
The average CAP was 255 6 62 dB/m; CAP was
greater than or equal to 220 dB/m in 132 patients
TABLE 1. BASELINE CHARACTERISTICS IN THE OVERALL POPULATION AND IN PATIENTS
DEVELOPING OR NOT DEVELOPING CLINICALLY RELEVANT EVENTS
Baseline Characteristics
Overall
(n 5 193)
Patients Developing
Clinically Relevant Events
(n 5 18)
Patients Remaining
Compensated
(n 5 175) P
Age (years) 56 (20-83) 58 (25-74) 54 (20-83) 0.77
Sex (male) (n [%]) 125 (65) 12 (67) 113 (65) 0.79
Etiology (n)
HCV 90 5 85
HBV 15 1 14
HCV 1 HBV 2 0 2
Alcohol 1 HCV 6 1 5
Alcohol 21 4 17
Nonalcoholic fatty liver disease 27 3 24
Cholestatic/autoimmune 20 2 18
Others 12 2 10
Nonviral/viral (n) 80/113 11/7 69/106 0.08
HCC at baseline (n) 4 1 3 0.73
BMI (kg/m2)* 26.5 (16.0-42.8) 27.5 (16.0-38.0) 26.3 (16.9-42.8) 0.66
Overweight (%) 82/183 (44.8) 10/17 (58.8) 72/166 (43.3)
Obese (%) 39/183 (21.3) 4/17 (23.5) 35/166 (21.0)
Dyslipidaemia (%) 21 22 21 0.77
Lipid-lowering drug (%) 9 11 9
Diabetes (%) 18 17 18 0.85
Diabetes therapy (%) 14 17 14
Arterial hypertension (%) 56 61 55 0.61
Antihypertensive drugs (%) 34 50 33
Nonselective beta-blockers (n [%]) 14 (7.3) 3 (16.7) 11 (6.3) 0.176
Child-Pugh score 5 (5-9) 5 (5-8) 5 (5-9) 0.24
MELD score 7 (6-20)† 7 (6-15) 7 (6-20)† 0.17
Alanine aminotransferase (U/L) 63 (7-296) 44 (15-204) 66 (7-296) 0.20
GGT (U/L) 110 (11-967) 211 (26-967) 96 (11-895) 0.02
Bilirubin (lmol/L) 13 (3-89) 16 (3-66) 13 (4-89) 0.133
Creatinine (lmol/L) 67 (39-463) 62 (48-90) 67 (39-463) 0.60
Albumin (g/L) 38 (23-45) 37 (26-44) 38 (23-45) 0.12
INR 1.04 (1.00-1.68) 1.09 (1.00-1.63) 1.03 (1.00-1.68) 0.01
Platelet count (g/L) 154 (30-456) 114 (36-312) 156 (30-456) 0.07
Spleen size (cm)‡ 12.3 (8-24) 13.9 (8-20) 12.0 (8-24) 0.17
LSM (kPa) 15.1 (10-75) 30.8 (11.8-75) 14.3 (10-75) <0.001
<13.6 kPa (%) 42 3.7 96.2
15.0 kPa (%) 50 77.7 47.5
 21.0 kPa (%) 33 81.1
Interquartile range/median 0.16 6 0.07 0.16 6 0.08 0.16 6 0.07 0.93
CAP (dB/m) 255 6 62 275 6 46 252 6 63 0.07
CAP IQR (dB/m) 37 (0-129) 47 (24-109) 36 (0-129) 0.29
CAP  220 dB/m (n [%]) 132 (68.0) 17 (94.4) 115 (65.8) 0.03
CAP  235 dB/m (n [%]) 112 (58.0) 15 (83.3) 97 (55.4) 0.03
Note: Percentages refer to the proportion of the population presenting the condition. Mean 6 standard deviation or median and range
are given according to the normality of distribution. P values were obtained using Cox univariate analysis.
*BMI was available in 183 patients.
†MELD 20 refers to one patient on dialysis.
‡Available in 110 patients.
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(68%) and greater than or equal to 235 dB/m in 112
patients (58%). Body mass index and CAP showed a
moderate positive correlation (R 5 0.323, P < 0.001),
and CAP increased across the BMI classes (Support-
ing Table S1). Patients with CAP greater than or equal
to 220 dB/m had a higher proportion of male gender,
a higher prevalence of diabetes, and higher BMI and
GGT as compared with patients with CAP less than
220 dB/m. In addition, they showed higher serum
albumin and lower Child-Pugh score (Table 2).
The LSM showed a median of 15.1 kPa (range 10-
75). Fifty percent of patients had a deﬁnite cACLD
according to the Baveno VI criteria (15 kPa). As for
the predeﬁned threshold for portal hypertension, 33%
of the population met the criteria for CSPH (21 kPa;
n 5 64) (Table 1). Patients with an LSM of 13.6 to
20.9 kPa had a lower proportion of obesity and a lower
CAP value as compared with patients in the low range
and high range of LSM (P 5 0.03; Kruskal-Wallis
test for differences among categories: P 5 0.013; Sup-
porting Table S2).
Clinical Events During Follow-up
Eighteen patients (9.3%) developed a ﬁrst relevant
clinical event during follow-up. Clinical decompensa-
tion of liver disease occurred in 11 patients as follows:
ascites (n 5 9; in 2 cases associated with bacterial
infection), variceal bleeding (n 5 1), and hepatic
encephalopathy (n 5 1). Seven additional patients
TABLE 2. COMPARISON OF THE BASELINE CHARACTERISTICS OF PATIENTS WITH CAP < 220 DB/M
VERSUS CAP  220 DB/M
Baseline Characteristics
CAP < 220 dB/m
(n 5 61)
CAP  220 dB/m
(n 5 132) P
Age (years) 55 (20-83) 55 (22-81) 0.96
Sex (male) (n [%]) 32 (53) 93 (71) 0.023
Etiology (n)
HCV 29 61
HBV 2 13 0.50
HCV 1 HBV 2 0
Alcohol 1 HCV 2 4
Alcohol 5 16
NAFLD 3 24
Cholestatic/autoimmune 12 8
Others 6 6
Nonviral/viral (n) 26/35 54/78 0.88
HCC at baseline (n) 1 3 1.0
BMI (kg/m2)* 24.4 (16.8-38.0) 27.8 (16-42.8) <0.001
Overweight (%) 19/56 (34) 63/127 (50) 0.05
Obese (%) 3/56 (5) 36/127 (28) <0.001
Dyslipidaemia (%) 18 23 0.57
Lipid-lowering drug (%) 7 10
Diabetes (n [%]) 9 (15) 26 (20) 0.05
Diabetes therapy (%) 12 15
Arterial hypertension (%) 49 59 0.21
Anti-hypertensive treatment (%) 31 36
Child-Pugh score 5 (5-9) 5 (5-8) 0.009
MELD score 7 (6-20)† 7 (6-16) 0.88
ALT (U/L) 57 (10-266) 72 (7-296) 0.23
GGT (U/L) 83 (11-864) 124 (24-967) 0.07
Bilirubin (lmol/L) 14 (4-89) 13 (3-66) 0.51
Creatinine (lmol/L) 63 (39-463) 68 (43-231) 0.33
Albumin (g/L) 36 (23-45) 39 (26-44) 0.01
INR 1.05 (1.0-1.26) 1.03 (1.0-1.68) 0.17
Platelet count (g/L) 154 (30-377) 154 (33-456) 0.91
Spleen size (cm)‡ 12.0 (8-24) 12.3 (8-20) 1.0
CAP (dB/m) 187 6 27 286 6 47 <0.001
CAP interquartile range (dB/m) 49 (0-129) 39 (0-109) 0.10
LSM (kPa) 14.7 (10-75) 16.1 (10-75). 0.57
Interquartile range/median 0.15 6 0.07 0.17 6 0.07 0.89
*BMI was available in 183 patients.
†Available in 110 patients.
‡MELD 20 refers to one patient on dialysis.
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developed a severe infection requiring hospitalization
(pneumonia in two, urinary tract infection in two, gas-
trointestinal infection in two, soft tissue infection in
one). Regarding the etiology of liver disease, seven rel-
evant clinical events were observed in patients with
viral disease (three occurring in patients who achieved
a sustained virological response following DAAs after
being included in the study), and 11 in nonviral disease
(alcohol in four, nonalcoholic steatohepatitis in three,
other in four).
Three of the 18 patients (16%) died during follow-
up. The cause of death was septic shock in two and
HCC in one.
A total of 175 patients remained compensated and
without severe bacterial infections. Among them, four
(2.3%) died: Two deaths were due to HCC and two
were unrelated to liver disease (extrahepatic cancer in
one; trauma in one).
As for other liver-related events, four patients were
transplanted during the follow-up.
Variables Associated With Clinically
Relevant Events (Clinical
Decompensation and Severe Bacterial
Infections) and Noninvasive Predictors
of Clinical Decompensation in cACLD
Table 1 lists the comparison of the baseline clinical
parameters in patients who developed decompensation
or severe bacterial infections versus patients who
remained compensated.
As shown, patients who developed relevant clinical
events had a slightly worse liver function (higher INR
and lower albumin) and lower platelet count (P 5
0.07). Among those patients having endoscopy avail-
able (n 5 93), 39 had esophageal varices. In the sub-
group with endoscopy available, the presence of varices
was not associated with the development of clinical
events (varices in 57% of those who decompensated
versus 39% of those remaining compensated; P 5
0.435). Patients developing events in the follow-up
featured higher GGT (275 6 46 versus 252 6 63, P
5 0.07) and CAP values in comparison to patients
remaining compensated (proportion with CAP  220
dB/m: 17 of 18 or 94.4% versus 115 of 175 or 65.8%,
P 5 0.03). Patients with CAP greater than or equal to
220 dB/m had a signiﬁcantly higher risk of clinical
events as compared with patients with CAP less than
220 dB/m (12.9% versus 1.6%, P 5 0.013) (Fig. 2).
As for the 11 episodes of ﬁrst clinical decompensation
of liver disease, 10 occurred in patients with CAP
greater than or equal to 220 dB/m (Supporting Fig.
S1).
Only one patient with CAP less than 220 dB/m
developed decompensation during follow-up (ascites
associated with partial portal vein thrombosis). This
patient was obese (BMI 38 kg/m2), diabetic, and had
an LSM of 20.4 kPa.
Diabetes and arterial hypertension were equally rep-
resented in patients developing or no clinical events,
and BMI was similar in the two groups; the proportion
of events in patients with normal BMI, overweight,
and obesity was 5% (3 of 60), 12.2% (10 of 82), and
10.2% (4 of 39), respectively (P 5 0.31).
The LSM was markedly higher in patients develop-
ing clinical events (33.6 6 19.2 versus 19.8 6 13.0
kPa in those remaining compensated, P < 0.001), and
the highest proportion of clinical events was observed
in patients with LSM greater than or equal to 21 kPa
(18.8% versus 6.3% in LSM, 13.6-20.9 kPa versus
3.7% in LSM < 13.6 kPa; P 5 0.006) (Fig. 3A), who
had the highest risk of clinical events over the follow-
up (Fig. 3B).
The different multivariate models that were tested
are provided in Table 3. As indicated, LSM and CAP
greater than or equal to 220 dB/m remained indepen-
dently associated with the ﬁrst clinically relevant event
in all of the tested models. Similarly, in a sensitivity
analysis performed with a CAP cut-off of 235 dB/m,
LS and CAP greater than or equal to 235 dB/m
remained independently associated with the ﬁrst
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FIG. 2. Risk of developing clinical decompensation in the
follow-up according to CAP being less than and greater than or
equal to 220 dB/m. As shown, patients with CAP being greater
than or equal to 220 dB/m had a signiﬁcantly higher probability
of developing clinical decompensation (log-rank P 5 0.012).
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FIG. 3. Clinical decompensation according to LSM. A, Proportion of patients developing decompensation according to previously
published LSM cut-offs for portal hypertension. All patients but one (belonging to the group with 13.6-21 kPa) had a CAP greater
than or equal to 220 dB/m. B, Risk of developing clinical decompensation over time according to different LSM cut-offs. As shown,
the highest risk was observed in patients with a LSM greater than or equal to 21 kPa (log-rank P 5 0.01).
                                                                                                                                      
TABLE 3. COX’S MULTIVARIATE STEPWISE REGRESSION ANALYSIS TO ANALYZE THE INDEPENDENT
EFFECT OF SELECTED VARIABLES ON THE RISK OF CLINICALLY RELEVANT EVENTS
Exp(B) 95% CI P Loss if term removed (P)
Model 1 Variables Tested: LSM, CAP  220 dB/m, Viral Etiology
LS
(per kPa)
1.04 1.02-1.07 <0.001 0.002
CAP  220 dB/m 6.66 0.88-50.5 0.067 0.015
Model 2 Variables Tested: LSM, CAP  220 dB/m, Albumin
LS
(per kPa)
1.04 1.02-1.06 0.001 0.002
CAP  220 dB/m 6.31 0.83-47.9 0.075 0.019
Model 3 Variables Tested: LSM, CAP  220 dB/m, GGT
LS
(per kPa)
1.04 1.02-1.07 <0.001 0.001
CAP  220 dB/m 6.38 0.84-48.4 0.073 0.018
Model 4 Variables Tested: LSM, CAP  220 dB/m, INR
LS
(per kPa)
1.05 1.02-1.07 <0.001 0.002
CAP  220 dB/m 4.73 0.61-36.9 0.138 0.068
Model 5 Variables Tested: LSM, CAP  220 dB/m, Platelet Count
LS
(per kPa)
1.05 1.02-1.07 <0.001 0.001
CAP  220 dB/m 6.42 0.85-48.5 0.072 0.017
Model 6 Variables Tested: LSM, CAP  235 dB/m
LS
(per kPa)
1.04 1.02-1.07 <0.001 0.001
CAP  235 dB/m 3.03 0.87-10.61 0.083 0.054
Model 7 Variables Tested in Patients With LS  15 kPa: LSM, CAP  220 dB/m
LS
(per kPa)
1.04 1.01-1.07 0.018 0.029
CAP  220 dB/m 4.53 0.58-35.2 0.149 0.076
Abbreviation: CI, conﬁdence interval.
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clinically relevant event (Table 3; Supporting Fig. S2).
Of note, the results were similar after restricting the
analysis to patients with deﬁnite cACLD according to
the Baveno VI criteria (LSM  15 kPa)(2) (Table 3),
in patients with viral and nonviral etiology of ACLD
(Supporting Fig. S3), and after excluding the 13
patients with BMI greater than 35 kg/m2 (data not
shown).
CAP as a Tool for Further Risk
Stratification in Patients With CSPH
Defined by LSM Greater Than or Equal
to 21 kPa
Among the 64 patients with LSM greater than or
equal to 21 kPa, 12 developed clinically relevant events.
None of them had a CAP less than 220 dB/m on
inclusion (Fig. 3A). On Cox regression, the probability
of developing relevant events over time was higher in
patients with CAP greater than or equal to 220 dB/m
versus patients with lower CAP (P 5 0.03) (Support-
ing Fig. S4). On multivariate analysis, including LS
and CAP greater than or equal to 220 dB/m, both var-
iables remained independently associated with the
development of relevant events.
Discussion
Risk stratiﬁcation in patients with cACLD is a cru-
cial need for personalizing medical care.(2) The NITs
are easily applicable and provide a quick point-of-care
risk stratiﬁcation that can be promptly integrated into
the clinical management. Among NITs, LSM, which
provides a quantitative estimation of liver ﬁbrosis, is
the best validated to identify cACLD(21) and to further
stratify the risk of clinical complications in cACLD.(7)
The major ﬁnding of our study is that CAP, a NIT
addressing liver fat content and obtained simultaneous
to LSM, adds precision to the risk stratiﬁcation for rel-
evant events and clinical decompensation obtained by
LSM alone in European patients with cACLD of dif-
ferent etiologies. Patients with CAP greater than or
equal to 220 dB/m in our study had a substantially
higher risk of developing clinical decompensation and
severe bacterial infections, and this additional predic-
tive value over that of LSM remained true also when
the analysis was restricted to the high-risk patients,
selected by LSM greater than or equal to 21 kPa, indi-
cating CSPH.
The CAP has been shown to reﬂect the presence
and severity of liver steatosis with high accuracy.(15)
Importantly, CAP detects steatosis independent of
liver ﬁbrosis stage,(15) and an increase in CAP value is
associated with the presence of steatosis even in
patients with advanced ﬁbrosis/cirrhosis, in whom
steatosis is known to decrease.(22,23) In our cohort,
patients with CAP less than 220 had a slightly higher
Child-Pugh score and a lower serum albumin as com-
pared with patients with CAP greater than or equal to
220 dB/m, which is in agreement with previous obser-
vations showing a lower fat content in patients with
more severe liver disease.(22,23) In contrast, although
CAP and LSM showed no signiﬁcant correlation,
CAP and BMI were positively and signiﬁcantly corre-
lated, and patients with higher CAP had higher preva-
lence of diabetes. These results are in line with several
other studies in different scenarios in chronic liver dis-
ease linking metabolic risk factors to higher CAP val-
ues as a biomarker of steatosis.(13,24)
In our patients, CAP greater than or equal to 220
dB/m was signiﬁcantly associated with clinically rele-
vant events independent of LSM. In this scenario, our
ﬁnding conﬁrms the previously reported association
between the presence of steatosis and further progres-
sion of liver disease in cACLD.(10) The choice of using
categorization and the choice of the cut-offs we used
depends on the observation that in the HALT-C study
cohort,(10) only the presence, but not the severity of
liver steatosis, remained associated with the progres-
sion of liver disease and clinical events. According to
this observation, false-negative results of a steatosis
biomarker (i.e., classifying a patient with steatosis as
not carrying it) would lead to “missed” high-risk
patients, with potentially serious consequences. There-
fore, we considered that a sensitive detection of
patients with liver steatosis had to be prioritized over
speciﬁcity in the choice of a CAP cut-off, and because
there is still a substantial uncertainty regarding which
CAP cut-off should be used, we arbitrarily decided to
choose 220 dB/m among those published with high
sensitivity,(11,16) and to analyze a second higher cut-
off, namely, 235 dB/m(17), to increase a conﬁdent
interpretation of the results. Our results diverge from
those recently published by Liu et al.(25) in an Asiatic
population; in their study, CAP showed no prognostic
predictive value for liver-related events. We do not
have a clear explanation for the observed difference,
and we hypothesize that might be inherent to differ-
ences in the population included (e.g., severity of the
disease, geographic origin).
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In the present study, LSM was the strongest predic-
tor of clinical events in the follow-up. Patients with
LSM greater than or equal to 21 kPa experienced most
of the events, therefore conﬁrming the results obtained
by Robic et al.(8) and reinforcing that patients with
LSM over this value should be considered at very high
risk, likely because of the presence of CSPH at base-
line. In addition, we observed that LSM (treated as a
continuous variable) maintains a strong predictive
value for clinical events beyond the cut-off used to
identify the presence of CSPH. This reinforces the
concept that continuous models of risk could be used
to improve personalization of care.(26)
Contrary to what was observed in a previous
study,(9) in this cohort BMI was not associated with
higher risk of clinical decompensation. We postulate
two possible explanations for this discrepancy. The
most likely is that this was due to the fact that when
conducting the study CAP was available only on M
probe, which made our results only applicable to
patients with a skin-to-capsule distance appropriate for
this probe. The lack of CAP values using the XL probe
is a clear limitation of our study, as most patients with
obesity and most patients with BMI greater than or
equal to 35 kg/m2 exceed the limits of the M
probe(27,28); therefore, obesity is underrepresented in
our cohort. However, despite the lack of predictive
value of BMI, CAP greater than or equal to 220 dB/m
remained associated with a higher risk of decompensa-
tion in our cohort, which suggests that this NIT could
help in reﬁning the prognosis even in patients with rel-
atively low BMI. Further studies using the XL probe
will clarify whether our results can be extrapolated to
obese patients with cACLD.
Another possible explanation might be that the cur-
rent deﬁnition of cACLD includes a spectrum of
advanced ﬁbrosis and cirrhosis(2,29); consequently, the
population included in the present study might be at
an earlier stage, on average, as compared with that
included in the Timolol study cohort.(9,30) Therefore,
the interaction among obesity, steatosis, ﬁbrosis, and
prognosis might not be identical and requires further
investigation. We consider, however, that this is less
likely, as the association between CAP and prognosis
was conﬁrmed when the analysis was restricted to
patients with an LSM greater than or equal to 21 kPa,
who have cirrhosis and CSPH (a more advanced popu-
lation than that of the Timolol study).
Our study has several limitations. First, it is a retro-
spective study, which implies the risk of an inclusion
bias. However, to minimize this, we included
consecutive patients strictly deﬁned according to pre
hoc rules. Second, in this cohort, no histological conﬁr-
mation of ﬁbrosis at the time of LSM/CAP assess-
ment was available, and we cannot provide data to
support whether the identiﬁcation of cACLD was cor-
rect. However, the rate of clinical events observed in
the follow-up is in agreement with that expected in
cACLD(31); furthermore, we were able to conﬁrm the
predictive value of CAP independent of LSM in the
subgroup of patients who have LSM greater than or
equal to 15 kPa. These patients have a deﬁnite
cACLD according to the Baveno VI consensus confer-
ence,(2,32) and most importantly, a LSM greater than
or equal to 21 kPa, indicating that they very likely have
CSPH.(7) Because liver biopsy was not available in the
study population, we cannot conﬁrm whether the
CAP-increased values genuinely mirror steatosis or
whether the increases are due to unknown factors in
cACLD; in any case, the CAP prognostic ability
remains tied to whatever components might contribute
to it. Interestingly, the CAP prognostic ability was
maintained both in viral and nonviral etiologies, and
several of our patients (similar to those reported in
other contemporary series) showed co-causes of liver
disease (e.g., viral1 metabolic, alcoholic 1 metabolic).
Therefore, we do not think that the inclusion of differ-
ent etiologies should be regarded as a major limitation.
Finally, the number of events and clinical decom-
pensation occurring in the follow-up is low. This is
inherent to the selection of the population of the study,
which consisted of many patients in an early stage of
cACLD. This also explains why in a relevant propor-
tion of the included patients an endoscopic screening
for esophageal varices was not available at inclusion, as
it was not deemed to be necessary by the physician in
charge of the patient. In contrast, our patients received
state-of-the-art treatment for the cause of liver disease,
including DAAs for HCV in most patients with
HCV-related cACLD, and this may have contributed
to decreasing the risk of decompensation.
However, the fact that even in these circumstances
CAP was independently associated with the risk of rel-
evant clinical events adds further value for the use of
this parameter in risk stratiﬁcation in clinical practice.
Severe bacterial infections leading to hospitalization
accounted for a signiﬁcant proportion of events and
were considered as clinically relevant events. This was
decided pre hoc in the design of the study due to the
increasingly recognized negative effect of infections as
worsening events in the natural history of cirrhosis,
regardless of its stage,(4,33) similar to the work
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published by Robic et al.(8) Importantly, even after
restricting the events to classical decompensating
events, CAP greater than or equal to 220 dB/m main-
tained a negative prognostic signiﬁcance, as observed
in 10 of 11 patients who decompensated (Supporting
Fig. S4).
The results of a recent study suggested that liver
stiffness changes over time provide additional prognos-
tic information in patients with cACLD(31) Future
studies are required to address the potential implica-
tions of longitudinal liver stiffness and CAP changes,
and their interaction for the prognostic stratiﬁcation in
this scenario.
In conclusion, in European patients with cACLD
diagnosed noninvasively by means of LSM, using
CAP with a cut-off of 220 dB/m improves the nonin-
vasive prediction of clinically relevant events (clinical
decompensation and severe bacterial infections), indi-
cating that it represents a simple and effective tool in
combination with LSM with no additional cost in this
scenario. The LSM is a strong predictor of clinically
relevant events in patients with cACLD, and its pre-
dictive value exceeds the simple identiﬁcation of the
CSPH stage, providing additional evidence for further
studies to address the personalization of management
according to individualized risk assessment based on
this parameter.
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